Roche announced the launch of Elecsys HBeAg quant, an immunoassay that is able to determine both the presence and quantity of the hepatitis B e antigen in human serum and plasma. “This launch means that, when combined with other laboratory results and clinical information, patients will now get confirmation on whether they have hepatitis B, and if so, to what extent, as well as treatment monitoring through one single assay. It is for use on the cobas e analysers in countries accepting the CE Mark,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
- Genentech and Nvidia in strategic drug discovery and development AI pact
- Roche launches automates serology hepatitis E virus tests
- Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List
- Roche subcutaneous injection of Tecentriq recommended by EU’s CHMP
